Assembly Biosciences (ASMB) Current Assets (2010 - 2026)

Assembly Biosciences' Current Assets history runs 17 years deep, the most recent figure standing at $232.6 million for Q1 2026.

• On a quarterly basis, Current Assets rose 143.5% year-over-year to $232.6 million in Q1 2026; TTM through Mar 2026 was $232.6 million, a 143.5% increase from a year earlier, with the FY2025 full-year figure at $254.5 million, up 120.38% from the prior year.
• Current Assets eased to $232.6 million in Q1 2026 per ASMB's latest filing, from $254.5 million in the prior quarter.
• Across five years, Current Assets topped out at $254.5 million in Q4 2025 and bottomed at $49.7 million in Q3 2023.
• The 5-year median for Current Assets is $115.1 million (2022), against an average of $125.6 million.
• Across the five-year window, Current Assets slumped 56.84% in 2023 and jumped 143.5% in 2026, its largest moves.
• Year by year, Current Assets stood at $97.0 million in 2022, then jumped by 37.97% to $133.8 million in 2023, then dropped by 13.67% to $115.5 million in 2024, then surged by 120.38% to $254.5 million in 2025, then declined by 8.62% to $232.6 million in 2026.
• Per Business Quant, the three latest ASMB Current Assets figures stand at $232.6 million (Q1 2026), $254.5 million (Q4 2025), and $236.8 million (Q3 2025).